Home / Market News / $RGNX
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Mizuho Cuts Price Target on REGENXBIO to $18 From $19

Nov 6, 2026, 1:09 PM UTC · Primary ticker $RGNX

Mizuho Securities has lowered its price target for REGENXBIO (RGNX) from $19 to $18, while maintaining an Outperform rating. This indicates a slightly reduced valuation outlook from the analyst, but still suggests a positive long-term view on the stock.

Mizuho Securities has adjusted its price target for REGENXBIO (RGNX) downwards from $19 to $18. This revision, while a slight negative, is somewhat mitigated by the firm's decision to maintain an 'Outperform' rating, suggesting continued confidence in the company's prospects despite a slightly lower valuation. This primarily affects RGNX shareholders and potential investors, as it signals a minor recalibration of analyst expectations. In the short term, this could lead to some minor selling pressure or a dampened sentiment, but the maintained 'Outperform' rating suggests that long-term investors might view this as a minor blip. The key risk for traders is potential overreaction to the price target cut, while the opportunity lies in recognizing the continued positive rating.

$RGNX negative Price target reduction
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.